Small-molecule GLP-1 receptor agonist · Fact sheet

Orforglipron

Also known as Foundayo · LY3502970

Orforglipron is the small-molecule GLP-1 medicine in Foundayo, FDA approved for weight management in defined adults. Trials show weight reduction, with gastrointestinal effects and important label warnings; it is not a peptide.

FDA approved for specific usesStrong human evidence for approved uses

What is Orforglipron?

Orforglipron activates the GLP-1 receptor through a non-peptide molecule. Its evidence and approval are product-specific.

Benefits & claims

Readers often compare its oral formulation, weight effects, appetite effects, and tolerability with semaglutide and tirzepatide. Separate placebo-controlled trials cannot establish a universal ranking.

What the evidence supports

  • ATTAIN-1 found greater weight reduction than placebo over 72 weeks in adults with obesity or qualifying overweight.
  • Evidence supports the defined weight-management indication; broader disease-prevention claims need their own outcomes studies.
Research areas
  • Adult weight management
  • Obesity-related metabolic measures
  • Type 2 diabetes research

Dosage & frequency

Product-specific label information

Foundayo is an oral GLP-1 receptor agonist with a product-specific adult weight-management titration. Its tablet amounts cannot be substituted for other GLP-1 medicines.

Foundayo

Adults meeting labeled weight-management criteria

Amount
0.8 → 2.5 → 5.5 mg; subsequent eligible steps 9, 14.5 and 17.2 mg
Frequency
Once daily; at least 30 days at each step
Route studied or labeled
Oral

Maximum 17.2 mg; interacting medicines can restrict or preclude this regimen.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Elimination half-life
Approximately 29–49 hours.

Formulation differences

  • Foundayo is a small molecule, not a peptide; it may be taken with or without food.

Interactions & precautions

  • Strong CYP3A4 or OATP1B-related interactions can change the permitted regimen; the label restricts or avoids specified combinations.

What is still unresolved

  • It is not an approved general longevity treatment.

Side effects & risks

  • Common effects include nausea, constipation, diarrhea, vomiting, abdominal symptoms, headache, fatigue, and hair loss.
  • The boxed warning addresses thyroid C-cell tumor risk; the human relevance of receptor-class rodent findings is uncertain. MTC/MEN2 history is a contraindication.
  • Warnings include pancreatitis, severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, allergy, and hypoglycemia with certain medicines.
  • Drug interactions, oral-contraceptive effects, pregnancy, retinopathy history, and anesthesia require product-specific clinical assessment.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

Phase 3 weight-management trials support the approved adult indication. Results for weight and metabolic markers should be distinguished from proof of fewer heart attacks, longer life, or every diabetes-related use.

Studies

ATTAIN-1 registry

Phase 3 trial of orforglipron in adults with obesity or overweight and related conditions.

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Appetite: reported experiences

Positive account · personal report

Less appetite with early weight loss

A different commenter described about two weeks of markedly reduced appetite and early weight loss.

Reported use in this account

Product
Product described as orforglipron; brand not stated
Amount
0.8 mg
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Two weeks

Weight was self-reported, with no baseline diet or activity record. The account cannot predict an expected amount of loss.

Read the original account
Mixed account · personal report

Initial craving relief later faded

Another commenter initially described reduced cravings and stomach upset with a product claimed to contain orforglipron. A later edit said the effect had become inadequate.

Reported use in this account

Product
Unapproved-market tablets claimed to contain orforglipron
Amount
3 mg, then 1.5 mg; later the author said both had become inadequate
Frequency
Not specified clearly
Route
Not specified clearly
Duration
About one month at the initial comment

The author explicitly described an unapproved-market product; contents and strength were unverified. This cannot be transferred to approved Foundayo.

Read the original account
Mixed account · personal report

Weight loss with worsening stomach problems

A commenter describing trial participation reported lower appetite and weight loss, but later stomach problems severe enough to consider leaving.

Reported use in this account

Product
Trial treatment believed by the commenter to be orforglipron; assignment not verified
Amount
2.5 mg is explicit; other amount numbers in the account have no stated unit
Frequency
Not specified clearly
Route
Not specified clearly
Duration
One month at the initial amount; total trial duration not stated

Enrollment and treatment assignment were not verified. A participant's belief about receiving active drug is not proof of allocation.

Read the original account

Approval status

FDA approved Foundayo on April 1, 2026, for reducing excess weight and maintaining weight reduction in adults with obesity or overweight with at least one weight-related condition, alongside diet and physical activity.

Approved uses

  • Foundayo: long-term weight reduction and maintenance in adults meeting the label’s obesity or overweight criteria

Foundayo FDA approved in 2026

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Longer-term outcomes in broader clinical use
  • Direct comparisons for specific patient-relevant outcomes
  • Uncommon harms beyond trial follow-up

Summary

Foundayo is approved for a defined adult weight-management use. Its product-specific risks and warnings remain central.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: Foundayo prescribing information

    Approved adult weight indication, contraindications, warnings, interactions, and clinical results.

  2. fdaFDA: novel drug approvals in 2026

    FDA approval dates and product-specific indications.

  3. journalATTAIN-1: orforglipron for obesity treatment

    Phase 3 randomized placebo-controlled trial with 72-week weight outcomes.

  4. clinical trialsATTAIN-1 registry

    Phase 3 trial of orforglipron in adults with obesity or overweight and related conditions.

How we assess sources · Suggest a correction